FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS)

Trial Details

NCT ID
NCT04625907
Phase
PHASE1 / PHASE2
Sponsor
University of Birmingham
Status
RECRUITING
Cancer Type
Rhabdomyosarcoma Sarcoma
Interventions
  • Irinotecan
  • Actinomycin D
  • Doxorubicin
  • Ifosfamide
  • Vincristine
  • Vinorelbine
Locations (sample)
  • Brisbane, Australia|-27.46794,153.02809
  • Camperdown, Australia|-33.88965,151.17642
  • Clayton, Australia|-37.91667,145.11667
  • Melbourne, Australia|-37.814,144.96332
  • New Lambton Heights, Australia|-32.92466,151.69364

Key Eligibility Criteria

  • Histologically confirmed diagnosis of RMS (except pleomorphic RMS)
  • Written informed consent from the patient and/or the parent/legal guardian
  • Phase 1b Dose Finding - IRIVA Inclusion
  • Entered in to the FaR-RMS study at diagnosis

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Rhabdomyosarcoma Sarcoma Trials on Trialify →